LLY241213C765000
- 25.00
- +5.40+27.55%
Eli Lilly and Co Newsroom
Eli Lilly (NYSE:LLY) Is Increasing Its Dividend To $1.50
Why Is Eli Lilly and Company (LLY) Among the Best Income Stocks to Buy According to Analysts?
Weekly Buzz: Tech stocks hit high scores on ominous day
Express News | "Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
Market Mixed on Friday the 13th | Livestock
Eli Lilly's Mounjaro Won't Have Separate Indication for Obstructive Sleep Apnea, European Regulator Says
EMA: Eli Lilly and Co (LLY.US) weight loss drug Mounjaro can also treat sleep apnea without the need for additional indications.
An expert panel of the EU pharmaceutical regulatory institution EMA has determined that Eli Lilly and Co's weight-loss drug Mounjaro does not require a separate indication for the treatment of obstructive sleep apnea (OSA).
Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.
Eli Lilly Gets Key European Backing for Omvoh in Crohn's Disease
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $994
Express News | Eli Lilly and Co - European Commission Decision on Omvoh Expected in Next 1-2 Months
Express News | Eli Lilly and Co - Expects U.S. Decision on Omvoh for Crohn's Disease in H1 2025
Express News | Lilly's Omvoh® (Mirikizumab) Recommended by Chmp for Approval in the European Union for Adults With Moderately to Severely Active Crohn's Disease
Express News | EMA's Chmp: Finalised Assessment of Application to Extend Use of Mounjaro to Include Treatment of Obstructive Sleep Apnoea in Adults With Obesity
Eli Lilly and Co (LLY.US) Mounjaro has replaced Novo-Nordisk A/S (NVO.US) Wegovy as the new favorite weight loss drug in the United Kingdom.
The number of private individuals in the United Kingdom purchasing weight loss drugs is continuously increasing, with Eli Lilly and Co's Mounjaro gradually surpassing Novo-Nordisk A/S's Wegovy, becoming a new favorite among consumers.
Lilly's Omvoh (Mirikizumab) Recommended by CHMP for Approval in the European Union for Adults With Moderately to Severely Active Crohn's Disease
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
Thursday Ends in Index Declines | Wall Street Today
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
TD Cowen Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,050